187 related articles for article (PubMed ID: 23233711)
1. Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib.
Kolar GR; Miller-Thomas MM; Schmidt RE; Simpson JR; Rich KM; Linette GP
J Clin Oncol; 2013 Jan; 31(3):e40-3. PubMed ID: 23233711
[No Abstract] [Full Text] [Related]
2. Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.
Tauber M; Pages C; La Selva R; Schneider P; Chardin J; Osio A; Mourah S; Culine S; Vercellino L; Bagot M; Lebbé C
Eur J Dermatol; 2013; 23(5):702-3. PubMed ID: 24135270
[No Abstract] [Full Text] [Related]
3. Vemurafenib as neoadjuvant treatment for unresectable regional metastatic melanoma.
Koers K; Francken AB; Haanen JB; Woerdeman LA; van der Hage JA
J Clin Oncol; 2013 Jun; 31(16):e251-3. PubMed ID: 23569313
[No Abstract] [Full Text] [Related]
4. Successful treatment with vemurafenib in BRAF V600K-positive cerebral melanoma metastasis.
Forschner A; Niessner H; Bauer J; Bender B; Garbe C; Meier F
JAMA Dermatol; 2013 May; 149(5):642-4. PubMed ID: 23677116
[No Abstract] [Full Text] [Related]
5. Absent response of intracranial melanoma metastases harboring BRAF V600E sequence variation to vemurafenib.
D'Alonzo D; Glatz K
Mayo Clin Proc; 2013 Dec; 88(12):e151-2. PubMed ID: 24290130
[No Abstract] [Full Text] [Related]
6. Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Kiyota N; Ejima Y; Nakajima K; Nishigori C
Eur J Dermatol; 2017 Apr; 27(2):177-178. PubMed ID: 27873735
[No Abstract] [Full Text] [Related]
7. Vemurafenib for melanoma metastases to the brain.
Rochet NM; Kottschade LA; Markovic SN
N Engl J Med; 2011 Dec; 365(25):2439-41. PubMed ID: 22188003
[No Abstract] [Full Text] [Related]
8. Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
Dzienis MR; Atkinson VG
Melanoma Res; 2014 Aug; 24(4):349-53. PubMed ID: 24709889
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib therapy for stage IV melanoma with V600G-mutation.
Lang N; Weisser A; Enk A; Hassel JC
J Dtsch Dermatol Ges; 2013 Dec; 11(12):1198-9. PubMed ID: 24016000
[No Abstract] [Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
11. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
12. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
14. Regression of orbital and choroidal metastases from melanoma after treatment with vemurafenib.
Ngo E; Hutchins LF; Gardner JM; Uwaydat SH
Can J Ophthalmol; 2014 Apr; 49(2):e49-52. PubMed ID: 24767240
[No Abstract] [Full Text] [Related]
15. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
Keating GM; Lyseng-Williamson KA
Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
[TBL] [Abstract][Full Text] [Related]
16. [Zelboraf. Longer term survival for advanced stage melanoma].
Sabourin G
Perspect Infirm; 2012; 9(5):64-5. PubMed ID: 22978138
[No Abstract] [Full Text] [Related]
17. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
[No Abstract] [Full Text] [Related]
18. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
Piérard-Franchimont C; Piérard GE
Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
[TBL] [Abstract][Full Text] [Related]
19. Fanconi syndrome induced by vemurafenib: a new renal adverse event.
Denis D; Franck N; Fichel F; Levi C; Dupin N
JAMA Dermatol; 2015 Apr; 151(4):453-4. PubMed ID: 25494458
[No Abstract] [Full Text] [Related]
20. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
